| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Digestive System |
Recent Updates
Recently added Catalysts
Corcept Therapeutics Incorporated$91.12
-4.24 (-4.45%)
B 62Pipeline Score Fair Value Pharma · Commercial
Market Cap
6.46 B
EPS
0.45
P/E Ratio
172.06 $
Value Trade
57.04 M
SEC Financials
Q1 2026Dilution Risk
Revenue
164.90 M
R&D Expenses
66.27 M
Operating CF
-16.77 M
Total Assets
814.88 M
Total Liabilities
176.89 M
Equity
637.99 M
D/E Ratio
12,345
4.84 %
Week
31.95 %
1 Month
77.27 %
3 Month
-19.81 %
6 Month
176.37 %
5 Year
391.59 %
All Time
Cash Data
Cash Position
338.18 M
Monthly Burn
5.59 M
Runway
57.6 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
1.42 M
52 Week Range
28.66 - 91
% held by Insiders
11.79 %
% held by Institutions
74.06 %
Enterprise Value
6.14 B
Total Shares
107.30 M
Short %
9.97 %
Float Shares
94.75 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Corcept Therapeutics Incorporated
802Total events
14Upcoming
205Tier-1 (high impact)
2007 – 2027Coverage
Upcoming catalysts 2
TBD
T1PDUFA Date
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
◆PDUFA DaterelacorilantFiledRegulatory Filing
Subscribe to view catalyst details
TBD
●NDA SubmissionrelacorilantFiledRegulatory Filing
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-07-11 | Relacorilant | PDUFA Date | PDUFA | Approved | – | – | – |
2026-07-11 | Relacorilant | PDUFA Date | PDUFA | Approved | – | – | – |
2026-07-11 | Relacorilant | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
B62
Pipeline Score $3.8B
Pipeline ValueFair Value
Valuation Signal22
Drugs Scored1.9x
rNPV / MCap Top 92%
Small Cap (rank 74 of 913)
Percentile RankCorcept Therapeutics Incorporated holds a solid B-grade pipeline (62/100), with $5.8B risk-adjusted pipeline value, led by Mifepristone in Weight-Gain Prevention (Phase 2), across $127B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mifepristone Small molecule | Cushing's Syndrome | Phase 3 | NCT00936741 | 54% | $1.2B | COMPLETED | 80 | - | - | Sep 1, 2012 | - | Apr 2, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Lifyorli | platinum-resistant ovarian cancer | Phase 3 | 2026-05-29 | hazard ratio: 0.65; median overall survival treatment: 16.0 months; median overall survival control: 11.9 months; hazard ratio taxane free interval: 0.6; hazard ratio recent taxane: 0.67 Read More | Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure Read More | |
Lifyorli | platinum-resistant ovarian cancer | Phase 3 | 2026-05-29 | hazard ratio: 0.65; median overall survival treatment: 16.0 months; median overall survival control: 11.9 months; hazard ratio taxane free interval: 0.6; hazard ratio recent taxane: 0.67 Read More | Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure Read More | |
Lifyorli | platinum-resistant ovarian cancer | Phase 3 | 2026-05-29 | hazard ratio: 0.65; median overall survival treatment: 16.0 months; median overall survival control: 11.9 months; hazard ratio taxane free interval: 0.6; hazard ratio recent taxane: 0.67 Read More | Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CORT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CORT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CORTPrevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study
The MOMENTUM study, presented at the 10th Annual Heart in Diabetes CME Conference, explores the prevalence of endogenous hypercortisolism in individuals with resistant hypertension, stratified by kidney function. The findings aim to enhance understanding of this condition and its implications for treatment. The presentation was made by Dr. Ralph A. DeFronzo.
Read more →CORTEfficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)
The Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10) presented findings on the efficacy and safety of Relacorilant combined with Nab-paclitaxel in treating platinum-resistant ovarian cancer in patients aged 65 and older. The results were shared at the European Society for Medical Oncology Gynaecological Cancers Annual Congress. The study's focus on older patients addresses a significant gap in treatment options.
Read more →CORTReal-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)
The COMPASS 2.0 study evaluates the comparative effectiveness of nab-paclitaxel versus standard chemotherapy in patients with platinum-resistant ovarian cancer. Presented by Dr. Mark S. Shahin at the European Society for Medical Oncology Gynaecological Cancers Annual Congress, the findings contribute valuable insights into treatment options for this challenging patient population.
Read more →CORTCorcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant, intended for the treatment of Cushing's syndrome. This resubmission follows previous interactions with the FDA. The company aims to address the needs of patients suffering from this condition with its investigational therapy.
Read more →CORTInvestor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome REDWOOD
Corcept Therapeutics announced the resubmission of its New Drug Application (NDA) for relacorilant as a treatment for Cushing's Syndrome to the FDA. This follows positive findings from clinical trials and incorporates additional analyses requested by the FDA. The company anticipates a six-month review period for the resubmitted application. CEO Joseph K. Belanoff expressed optimism about the drug's potential to provide significant benefits to patients, while also acknowledging the uncertainty of the regulatory process.
Read more →CORTEndogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies
The article discusses the presentation of results from two large prospective studies on endogenous hypercortisolism in patients with resistant hypertension and difficult-to-control type 2 diabetes. The findings were presented by Dr. Ralph DeFronzo at the Endocrine Society Annual Meeting in Chicago. This research highlights important health implications for managing these conditions.
Read more →CORTCharacterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol 1.8 μg/dL: Results From the MOMENTUM Study
The MOMENTUM Study results were presented at the Endocrine Society Annual Meeting, highlighting the characterization of individuals with resistant hypertension and their cortisol levels post-dexamethasone suppression test. The findings may provide valuable insights into managing this condition. The study emphasizes the importance of cortisol measurements in understanding hypertension resistance.
Read more →CORTHigh Prevalence of Endogenous Hypercortisolism in Patients With Type 2 Diabetes and Resistant Hypertension: Results From the MOMENTUM Study
The MOMENTUM study presented by Dr. Guillermo Umpierrez at the American Diabetes Association Scientific Sessions revealed a high prevalence of endogenous hypercortisolism in patients with type 2 diabetes and resistant hypertension. This research adds important knowledge to the understanding of the interplay between these conditions. The findings were shared at a prominent scientific event in New Orleans.
Read more →CORTEffects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs
The presentation titled 'Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs' was delivered by Dr. Lance A. Sloan at the American Diabetes Association Scientific Sessions on June 6, 2026. It discusses the impact of mifepristone on patients struggling with type 2 diabetes and hypercortisolism, particularly in relation to GLP-1 receptor agonists.
Read more →CORTCorcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Corcept has presented new data at the ADA conference regarding the outcomes of patients with difficult-to-control Type 2 diabetes and hypercortisolism treated with Korlym®. The findings suggest improvements in patient outcomes when Korlym® is used alongside GLP-1 receptor agonists. Further details on the data and implications for treatment were highlighted during the presentation.
Read more →CORTSYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies
The SYNERGY study investigates the efficacy of nenocorilant combined with nivolumab in patients with advanced solid tumors. Presented by Dr. Omid Hamid at the American Society of Clinical Oncology Annual Meeting, this Phase 1b/2 trial aims to provide insights into this innovative treatment approach. The findings may contribute to new therapeutic strategies in oncology.
Read more →CORTTRIDENT: A Phase 2 Study of Relacorilant Plus Nab-paclitaxel and Gemcitabine in Chemotherapy-naïve Patients With Metastatic Pancreatic Ductal Adenocarcinoma
The TRIDENT study investigates the efficacy of relacorilant combined with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic ductal adenocarcinoma. Presented at the American Society of Clinical Oncology Annual Meeting, the study aims to provide insights into new treatment options for this challenging cancer type.
Read more →CORTOverall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer
The Phase 3 ROSELLA trial results were presented at the American Society of Clinical Oncology Annual Meeting, highlighting the overall survival subgroup analyses for patients with platinum-resistant ovarian cancer. The study compares the efficacy of relacorilant plus nab-paclitaxel against nab-paclitaxel monotherapy, focusing on patients with prior taxane use. The findings suggest potential benefits of the combination therapy.
Read more →CORTCorcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
Corcept has presented new data at ASCO 2026 regarding Lifyorli™ and its overall survival benefits for patients with platinum-resistant ovarian cancer. The data includes insights across all patient subgroups, particularly those with recent taxane exposure. This presentation highlights the ongoing research and potential impact of Lifyorli™ in treating this challenging cancer type.
Read more →CORT▲ +10.4%on this newsshared move
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Corcept Therapeutics plans to resubmit its New Drug Application for relacorilant, aimed at treating patients with Cushing's syndrome. This decision follows previous interactions with the FDA regarding the drug's approval process. The company is focused on addressing any concerns raised during the initial review to facilitate a successful resubmission.
Read more →CORT▲ +10.5%on this news
Corcept Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Corcept Therapeutics reported a revenue increase to $164.9 million for Q1 2026, despite a net loss of $0.30 per share. The FDA's early approval of Lifyorli for treating platinum-resistant ovarian cancer marks a significant milestone. The company has raised its revenue guidance for the year and anticipates returning to profitability in Q2 2026.
Read more →CORTCorcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
Corcept Therapeutics announced promising two-year overall survival data from its Phase 2 DAZALS study of dazucorilant in ALS patients. While the study did not meet its primary endpoint, significant survival benefits were observed, with an 87% reduction in risk of death for patients receiving the higher dose. Corcept aims to advance the treatment into a pivotal Phase 3 study later this year.
Read more →CORTCorcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
Corcept Therapeutics reported a revenue increase to $164.9 million for Q1 2026, alongside a significant rise in operating expenses to $214.5 million, resulting in a net loss per share of $0.30. The company received FDA approval for Lifyorli to treat platinum-resistant ovarian cancer, enhancing its oncology portfolio. Corcept has raised its revenue guidance for 2026 and anticipates returning to profitability in the upcoming quarter.
Read more →CORTCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics will announce its first quarter financial results on April 30, 2026, and provide a corporate update. A conference call will follow at 5:00 p.m. ET, with registration required for participants. The company has a history of developing treatments for serious disorders, including recent FDA approvals.
Read more →CORTCORCEPT DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT
Corcept Therapeutics is facing a class action lawsuit due to alleged misrepresentations concerning the approval prospects of relacorilant. The lawsuit highlights that the FDA had raised concerns about the clinical evidence for the New Drug Application, contrary to the company's positive claims. Investors who purchased Corcept common stock during the specified Class Period may be entitled to compensation, and they need to act before the April 21, 2026 deadline to participate in the case. The Rosen Law Firm is encouraging investors to seek qualified counsel for representation.
Read more →CORTCorcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
Corcept Therapeutics will present new findings from its pivotal Phase 3 ROSELLA trial at the 2026 ASCO meeting. The trial evaluates Lifyorli™ (relacorilant) in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer. This presentation marks a significant step in the development of treatments for this challenging condition.
Read more →CORTCORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Corcept Therapeutics Incorporated Investors to Contact the Firm Regarding Their Rights Before April 21st
Bragar Eagel & Squire, P.C. is encouraging investors of Corcept Therapeutics who suffered losses between October 31, 2024, and December 30, 2025, to contact the firm regarding their legal rights. A class action lawsuit has been filed against Corcept, stemming from the FDA's Complete Response Letter on their NDA for relacorilant, a treatment for hypercortisolism. This letter indicated inadequacies in the clinical evidence presented by the company, leading to a significant drop in Corcept's stock price.
Read more →CORTCorcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
Corcept Therapeutics is currently facing a class action lawsuit for allegedly failing to disclose crucial information to investors related to its product candidate, relacorilant. The lawsuit claims that the company's representatives misled investors regarding the likelihood of FDA approval for relacorilant. Following the FDA's Complete Response Letter on December 31, 2025, which outlined the need for additional evidence to assess the drug's efficacy, Corcept's stock plummeted by over 50%. ClaimFiler is advising investors with losses exceeding $100,000 to file lead plaintiff applications by April 21, 2026.
Read more →CORTCorcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Corcept Therapeutics is currently facing a securities class action lawsuit due to allegations of failing to disclose critical information about its new product candidate relacorilant. Investors are urged to file lead plaintiff applications by April 21, 2026. This legal action follows the FDA's issuance of a Complete Response Letter, citing a lack of sufficient evidence for the product's effectiveness, which led to a significant decline in the company's stock price. The lawsuit is pending in the Northern District of California.
Read more →CORTCorcept Therapeutics Incorporated Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – CORT
Corcept Therapeutics has been named in a class action securities lawsuit due to alleged fraud involving false statements made regarding their drug relacorilant. The lawsuit, filed by Levi & Korsinsky, focuses on misleading claims made by the company about its interactions with the FDA and the anticipated approval of the drug, which may have misled investors. The time frame for the alleged fraudulent activity spans from October 31, 2024, to December 30, 2025. Affected investors have until April 21, 2026, to appoint a lead plaintiff in the case and may be eligible for compensation without incurring fees.
Read more →CORTRiassunto: Corcept presenta i dati completi dello studio clinico di fase III ROSELLA nelle notizie dell'ultima ora dell'SGO con la pubblicazione simultanea in The Lancet: Lifyorli™ (relacorilant) in combinazione con nab-paclitaxel migliora la sopravvivenza...
Corcept Therapeutics has presented final data from its Phase III ROSELLA study, showing that Lifyorli™ (relacorilant) combined with nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer patients. This announcement was made during an oral presentation at the 2026 Society of Gynecologic Oncology annual meeting and simultaneously published in The Lancet.
Read more →CORTSamenvatting: Corcept presenteert volledige gegevens van het cruciale ROSELLA-onderzoek tijdens de SGO late-breaker sessie, met gelijktijdige publicatie in The Lancet: Lifyorli™ (relacorilant) in combinatie met nab-paclitaxel verbetert de totale overleving bij...
Corcept Therapeutics has presented final data from its pivotal ROSELLA study, demonstrating that Lifyorli™ (relacorilant) in combination with nab-paclitaxel significantly improves overall survival in patients with platinum-resistant ovarian cancer. This data was shared during the Society of Gynecologic Oncology's annual meeting and published simultaneously in The Lancet.
Read more →CORTResumen: Corcept presenta en el Congreso de la SGO los resultados completos del ensayo clínico ROSELLA, publicados simultáneamente en The Lancet: Lifyorli™ (relacorilant) en combinación con nab-paclitaxel prolonga la supervivencia de pacientes con cáncer...
Corcept Therapeutics has announced the final results of its Phase 3 ROSELLA clinical trial, which evaluated Lifyorli™ (relacorilant) in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The findings, which indicate a prolongation of survival, were presented at the Society of Gynecologic Oncology's annual meeting and published in The Lancet.
Read more →CORTCorcept präsentiert vollständige Daten aus der zulassungsrelevanten ROSELLA-Studie im Rahmen einer Late-Breaker-Präsentation auf der SGO-Konferenz, begleitet von einer gleichzeitigen Veröffentlichung in The Lancet: Lifyorli™ (Relacorilant) Plus...
Corcept Therapeutics presented complete data from the ROSELLA study at the SGO conference, demonstrating that Lifyorli (Relacorilant) combined with Nab-Paclitaxel significantly improves overall survival in patients with platinum-resistant ovarian cancer. The findings, published in The Lancet, have led to Lifyorli being included in NCCN guidelines as a preferred treatment. The FDA has approved Lifyorli for patients who have undergone prior therapies, marking a significant advancement in treatment options.
Read more →CORTCorcept présente les données complètes de l'essai pivot ROSELLA dans le cadre d'une présentation de dernière minute au congrès de la SGO, avec une publication simultanée dans The Lancet : Lifyorli™ (rélacorilant) plus nab-paclitaxel améliore la…
Corcept Therapeutics presented complete data from the Phase 3 ROSELLA trial at the SGO conference, showing that Lifyorli (relacorilant) combined with nab-paclitaxel significantly improves overall survival in platinum-resistant ovarian cancer patients. The findings were published in The Lancet and have led to the treatment being included in the NCCN Guidelines. The trial demonstrated a 35% reduction in the risk of death compared to nab-paclitaxel alone, with manageable side effects.
Read more →CORTCorcept Therapeutics Incorporated Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 21, 2026 to Discuss Your Rights – CORT
Corcept Therapeutics Incorporated has been sued in a class action securities lawsuit by Levi & Korsinsky, LLP. The lawsuit seeks to recover losses from investors who were affected by alleged securities fraud between October 31, 2024, and December 30, 2025. The complaint alleges that the company made misleading statements regarding its interactions with the FDA, particularly concerning the adequacy of its program for relacorilant, which could impact the approval of its new drug application (NDA). Investors have until April 21, 2026, to seek lead plaintiff status.
Read more →CORTCorcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
Corcept Therapeutics presented data from its MOMENTUM trial at the ACC 2026, revealing that 27.3% of patients with resistant hypertension had hypercortisolism. This finding highlights the need for screening in these patients to improve treatment outcomes. The study reinforces previous findings from the CATALYST trial and emphasizes the importance of recognizing hypercortisolism in difficult-to-treat cases.
Read more →CORTLa FDA aprobó Lifyorli™ (relacorilant), el antagonista selectivo del receptor de glucocorticoides de Corcept, en combinación con nab-paclitaxel para el tratamiento de pacientes con cáncer de ovario resistente al platino
The FDA has granted approval for Lifyorli™ (relacorilant), a selective glucocorticoid receptor antagonist developed by Corcept. This drug is now authorized for use in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer. This approval marks a notable advancement in therapeutic options for this challenging patient population.
Read more →CORT▲ +19.7%on this newsshared move
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
The FDA has granted approval for Corcept's Lifyorli™ (relacorilant) in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer. This approval represents a crucial advancement in therapy options for this challenging patient population. The combination aims to improve treatment outcomes and provide new hope for affected individuals.
Read more →CORT▲ +19.7%on this newsshared move
Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli (relacorilant) Plus Nab-Paclitaxel for
Corcept Therapeutics has received FDA approval for Lifyorli (relacorilant) in combination with nab-paclitaxel, aimed at treating adults with platinum-resistant ovarian cancer. The approval was based on the ROSELLA trial results, which showed that patients using Lifyorli had improved overall survival rates and reduced disease progression compared to those on nab-paclitaxel alone. Lifyorli is recognized as the first FDA-approved selective glucocorticoid receptor antagonist for this condition, marking a significant milestone in cancer treatment options. However, potential side effects include neutropenia and severe infections, necessitating careful monitoring of patients.
Read more →CORTCorcept Therapeutics Incorporated Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 21, 2026 to Discuss Your Rights – CORT
A class action securities fraud lawsuit has been filed against Corcept Therapeutics by Levi & Korsinsky, LLP, on behalf of investors who incurred losses between October 31, 2024 and December 30, 2025. The lawsuit claims that the company made false statements regarding its interactions with the FDA, particularly concerning the effectiveness of relacorilant in treating hypertension. It suggests that Corcept was aware of significant issues that would arise from a potential NDA submission. Investors affected by these claims are encouraged to contact Levi & Korsinsky for legal representation.
Read more →CORTCORCEPT THERAPEUTICS INCORPORATED (CORT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Corcept Therapeutics Incorporated Investors of Upcoming Deadline
Bernstein Liebhard LLP has alerted investors of Corcept Therapeutics Inc. regarding an impending deadline related to a securities fraud class action lawsuit. This lawsuit involves allegations against the company for misrepresentations concerning their lead product candidate, relacorilant. Shareholders who acquired shares between October 31, 2024, and December 30, 2025, may be entitled to participate in the litigation process. The deadline for filing as a lead plaintiff is April 21, 2026.
Read more →CORTCorcept Therapeutics Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is conducting an investigation into Corcept Therapeutics following significant declines in its stock price. The investigation centers on potential securities law violations related to the company's new drug application for relacorilant, which was met with a Complete Response Letter from the FDA. Following the disclosure of FDA concerns regarding the adequacy of Corcept's clinical development program, shares dropped drastically, prompting Johnson Fistel to seek out affected investors for potential claims.
Read more →CORTCorcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
Corcept Therapeutics is currently involved in a securities class action lawsuit filed by Hagens Berman, alleging the company misled investors about its lead drug candidate, relacorilant. The lawsuit cites concerns raised by the FDA regarding the adequacy of the clinical development program and claims the company withheld warnings from shareholders. Following the receipt of a Complete Response Letter from the FDA, the company's stock experienced a dramatic decline, erasing more than $3.6 billion in market value. Investors have until April 21, 2026, to participate in the lawsuit.
Read more →CORTCorcept Therapeutics (CORT) Litigation: Hagens Berman Alerts CORT Investors to Securities Class Action and April 21 Lead Plaintiff Deadline
Corcept Therapeutics is embroiled in a securities class action lawsuit that alleges the company misled investors regarding the regulatory viability of its lead product, relacorilant. The complaint states that Corcept's management received warnings from the FDA about the inadequacy of clinical data yet assured investors of its favorable approval prospects. Following the revelation of a Complete Response Letter from the FDA indicating that relacorilant could not meet the benefit-risk assessment, the company's share price plunged dramatically, resulting in significant market value loss. Investors are encouraged to participate in the litigation before the approaching deadline of April 21, 2026.
Read more →CORTCorcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
Corcept Therapeutics reported strong financial results for Q4 and full-year 2025, with a notable increase in demand for its Cushing's syndrome treatments. The company faced some capacity constraints and operational disruptions but is optimistic about future growth and FDA approvals for its drug relacorilant. Upcoming clinical trial results are also anticipated to provide significant data.
Read more →CORTCORCEPT CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against Corcept Therapeutics, related to misrepresentations about the FDA's stance on their drug relacorilant. The lawsuit claims that investors were not informed of the risks related to the New Drug Application (NDA) for relacorilant during the designated class period. On December 31, 2025, the FDA issued a Complete Response Letter indicating insufficient clinical evidence for approval, which resulted in a significant drop in the company's stock price. Investors are being encouraged to discuss their legal options and those affected have until April 21, 2026, to apply as lead plaintiffs.
Read more →CORTCORCEPT THERAPEUTICS INCORPORATED (CORT) INVESTOR ALERT Investors With Large Losses in Corcept Therapeutics Incorporated Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Bernstein Liebhard LLP has announced a securities class action lawsuit against Corcept Therapeutics, targeting investors who acquired shares between October 31, 2024, and December 30, 2025. The lawsuit alleges that the company misrepresented the clinical evidence related to its lead product candidate, relacorilant, which is intended for treating hypercortisolism. Shareholders wishing to take part in the suit must file by April 21, 2026, and can participate without being lead plaintiffs.
Read more →CORT▼ -14%on this newsshared move
Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals REDWOOD CITY , Calif., (
Corcept Therapeutics has reported a negative outcome in its patent dispute with Teva Pharmaceuticals, with the United States Court of Appeals ruling that Teva's generic version of Korlym does not infringe on Corcept's patents. This ruling affirms a previous decision made by the Federal District Court and has led to disappointment from Corcept's CEO, who stated their commitment to defending their intellectual property rights. Corcept is now evaluating options for a possible judicial review of the appellate court's decision.
Read more →CORT▼ -14%on this newsshared move
CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated
Bernstein Liebhard LLP is investigating Corcept Therapeutics Inc. for potential violations of federal securities laws following the issuance of a Complete Response Letter by the FDA regarding its New Drug Application for the drug relacorilant. The FDA's letter noted that while clinical trials met primary endpoints, additional evidence is needed to assess the drug's benefit-risk profile. Consequently, Corcept's stock plummeted 50.42%, leading to significant financial losses for shareholders. The law firm is reaching out to affected shareholders to discuss potential legal rights and options.
Read more →CORTCorcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics will announce its fourth quarter and full-year 2025 financial results on February 24, 2026. The company will provide a corporate update and host a conference call at 5:00 p.m. ET. Participants must register in advance for the call, and a replay will be available afterward. Corcept has a strong portfolio in cortisol modulation and ongoing clinical trials.
Read more →CORTCORCEPT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Encourages Corcept Therapeutics Investors to Contact the Firm Regarding Ongoing Investigation
Bragar Eagel & Squire, P.C. is urging investors of Corcept Therapeutics (CORT) who experienced financial losses due to a major stock drop to come forward. The law firm is investigating whether Corcept violated federal securities laws related to the FDA's Complete Response Letter concerning its drug relacorilant. Following the announcement on December 31, 2025, Corcept's stock plummeted by over 50%, signaling potential risks for stockholders. Investors are encouraged to discuss their legal options with the firm, emphasizing a serious situation for Corcept going forward.
Read more →CORT▲ +6.5%on this news
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics announced that its Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel met its primary endpoint for overall survival in patients with platinum-resistant ovarian cancer. Patients receiving the combination therapy experienced a 35% reduction in the risk of death compared to those on nab-paclitaxel alone. The treatment was well-tolerated, maintaining a safety profile similar to the monotherapy. Corcept aims to expedite regulatory approval for this promising therapy.
Read more →CORT▲ +13.7%on this news· ran to +27% by day 3shared move
Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Pl
Corcept Therapeutics announced that its pivotal Phase 3 ROSELLA trial for relacorilant combined with nab-paclitaxel met its overall survival primary endpoint in patients with platinum-resistant ovarian cancer. The study showed a 35% reduction in the risk of death with a median overall survival of 16.0 months for patients receiving the combination therapy. This treatment is well-tolerated and does not increase the safety burden for patients. The successful results prompt further evaluation of relacorilant for earlier-stage ovarian cancer and other tumors expressing glucocorticoid receptors.
Read more →CORTCorcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman
Corcept Therapeutics (CORT) experienced a drastic 50% drop in its share price after receiving a Complete Response Letter (CRL) from the FDA regarding its treatment relacorilant for hypercortisolism. The FDA concluded it could not assess the benefit-risk ratio without more evidence of the drug's effectiveness. In light of this news, Hagens Berman has launched an investigation into possible misrepresentations by Corcept concerning relacorilant's efficacy and commercial prospects, which previously included optimistic forecasts of significant revenue growth. The investigation comes after the stock’s collapse eliminated more than $3.6 billion from the company’s market value in a single day.
Read more →CORTCORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics Incorporated on Behalf of Corcept Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Corcept Therapeutics on behalf of its stockholders due to a significant decline in stock value. This drop was triggered by the FDA issuing a Complete Response Letter for relacorilant, indicating insufficient evidence for efficacy. The law firm is encouraging affected investors to seek legal advice regarding their rights following this adverse news.
Read more →CORT▲ +9.8%on this newsshared move
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
Corcept Therapeutics received a Complete Response Letter from the FDA regarding its New Drug Application for relacorilant, intended for treating hypertension due to hypercortisolism. Although the pivotal GRACE trial met its primary endpoint, the FDA concluded that more evidence of effectiveness is needed. Corcept plans to meet with the FDA to discuss future steps.
Read more →CORT▼ -50.4%on this newsshared move
Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism REDWOOD
Corcept Therapeutics has received a Complete Response Letter from the FDA regarding its New Drug Application for relacorilant as a treatment for hypercortisolism. Despite the success of the pivotal GRACE trial and supportive data from the GRADIENT trial, the FDA requires further evidence of the drug's effectiveness before proceeding. The company plans to meet with the FDA to discuss potential next steps. Relacorilant has orphan drug designation for hypercortisolism and is also under development for ovarian cancer.
Read more →CORTCorcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update Revenue of $207.6 million, compared to $182.5 million in third quarter 2024 Modified 2025 revenu
Corcept Therapeutics reported a revenue increase to $207.6 million for Q3 2025, up from $182.5 million in Q3 2024. The company modified its 2025 revenue guidance upward to $800 - $850 million, reflecting growth in its hypercortisolism business. However, net income fell to $19.7 million, significantly lower than the previous year's $47.2 million. New oncology development programs are underway, alongside several key clinical trials expected to yield significant data in the coming months.
Read more →CORTInvestor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovaria
Corcept Therapeutics announced the acceptance of its New Drug Application (NDA) by the FDA for relacorilant, intended for treating platinum-resistant ovarian cancer. The FDA set a Prescription Drug User Fee Act (PDUFA) date for review on July 11, 2026. Clinical trials demonstrated that relacorilant, in combination with nab-paclitaxel, improved both progression-free and overall survival rates among patients compared to monotherapy. The drug is expected to offer a new treatment avenue for patients, who currently have few alternatives.
Read more →CORTCorcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update Revenue of $194.4 million, compared to $163.8 million in second quarter 2024 Modified 2025 revenue guidance of $850 - $900 mil
Corcept Therapeutics reported strong financial results for the second quarter of 2025, with revenue increasing to $194.4 million compared to $163.8 million in the same quarter of 2024. The company has adjusted its 2025 revenue guidance upward to between $850 and $900 million, reflecting robust growth in the hypercortisolism business. Key clinical developments included successful results from the CATALYST and ROSELLA studies, as well as progress on two New Drug Applications. Despite these advances, Corcept faced rising operational expenses and challenges with specialty pharmacy capacity.
Read more →CORTInvestor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Ca
Corcept Therapeutics has submitted a New Drug Application for relacorilant to treat platinum-resistant ovarian cancer, based on positive trial data. The application demonstrates improved progression-free and overall survival rates for patients receiving relacorilant in combination with nab-paclitaxel. The treatment has a favorable safety profile, aligning with expectations from previous studies. Corcept's submission is significant as the company also has another NDA pending for relacorilant in treating hypercortisolism, highlighting its commitment to advancing oncology therapies.
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Revenue of $157.2 million, compared to $146.8 million in first quarter 2024 Reiterated 2025 revenue guidance of $900 - $950 mil
Corcept Therapeutics reported a revenue increase to $157.2 million for Q1 2025, up from $146.8 million a year prior. Despite the growth, the net income per share fell to $0.17, down from $0.25, highlighting increased operating costs of $153.8 million. The company reiterated its guidance for 2025 revenue, projecting $900-$950 million, fueled by the anticipated approval of relacorilant for hypercortisolism and ongoing clinical trials for various indications. The leadership emphasized the need for improved pharmacy operations to meet rising prescription demands, which initially impacted financial results.
Read more →CORT▲ +109.1%on this news
Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com PRIMARY ENDPOINT MET IN CORCEPT S PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PATIENTS WITH PLATINUM-RESISTANT
Corcept Therapeutics announced that its pivotal Phase 3 ROSELLA trial for relacorilant in patients with platinum-resistant ovarian cancer successfully met its primary endpoint of improved progression-free survival. Patients receiving relacorilant alongside nab-paclitaxel exhibited a 30% lower risk of disease progression and enhanced overall survival. The trial involved 381 patients across multiple countries, and results demonstrate a promising potential for relacorilant as a new treatment strategy. The company plans to submit its New Drug Application (NDA) in the third quarter of this year.
Read more →CORTInvestor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com FDA FILES CORCEPT S NEW DRUG APPLICATION FOR RELACORILANT AS TREATMENT FOR PATIENTS WITH HYPERCORTISOLISM FDA assign
Corcept Therapeutics has announced that the FDA has accepted its New Drug Application for relacorilant, aimed at treating patients with hypercortisolism. This decision follows positive results from multiple pivotal trials, including the GRACE and GRADIENT trials, which show that relacorilant is effective and well-tolerated. The drug is designed to modulate cortisol effectively without serious adverse reactions associated with existing treatments. With a target action date set for December 30, 2025, Corcept is hopeful for relacorilant's potential as a new standard of care.
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2024 AUDITED FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE 2024 revenue of $675.0 million, a 40 percent increase over 2023 2025 revenue guidance of $900 - $95
Corcept Therapeutics announced its fourth quarter and full-year 2024 financial results, reporting a 40% increase in revenue to $675 million. The company provided optimistic projections for 2025, estimating revenues between $900 million and $950 million. Notably, there was a record growth in the number of prescribers and patients using their drug, Korlym, highlighting a growing awareness of hypercortisolism. Furthermore, the company submitted a New Drug Application for relacorilant, its selective cortisol modulator, based on positive clinical trial outcomes.
Read more →CORTInvestor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com CORCEPT SUBMITS NEW DRUG APPLICATION FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH HYPERCORTISOLISM REDWOOD CITY
Corcept Therapeutics has submitted a new drug application for relacorilant, targeting endogenous hypercortisolism (Cushing's syndrome). The application is supported by positive results from the GRACE trial and further studies, which indicate significant improvements in symptoms without serious side effects commonly associated with existing treatments. The company aims to position relacorilant as a new standard of care, reflecting its commitment to treating this challenging condition effectively.
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS, POSITIVE RESULTS FROM PHASE 3 GRADIENT TRIAL IN PATIENTS WITH CUSHING'S SYNDROME AND PROVIDES CORPORATE UPDATE Revenue of $182.5 million, a 48 percent incre
Corcept Therapeutics announced its third quarter financial results, revealing a revenue of $182.5 million, a 48% increase compared to the same quarter last year. The company raised its 2024 revenue guidance to between $675 million and $700 million, reflecting strong market performance. Positive outcomes from the Phase 3 GRADIENT trial support the NDA submission for relacorilant as a treatment for Cushing's syndrome. The company continues to develop its clinical programs, with several study results expected by year-end that could further boost its market position.
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif., (
Corcept Therapeutics reported strong financial results for Q2 2024, with revenues reaching $163.8 million, a 39% increase year-over-year. The company also raised its revenue guidance for the year, reflecting positive growth. Significant progress was made in clinical development, particularly with relacorilant, which is crucial to treatment for Cushing's syndrome and has shown promise in recent trials. The results from several studies are expected by the end of this year, setting the stage for potential new drug applications.
Read more →CORTCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics announced it will release its second quarter financial results on July 29, 2024, followed by a corporate update and a conference call. Participants can register to join the call, which will also feature a listen-only webcast. The company has a strong focus on cortisol modulation, developing treatments for various serious disorders, including hypercortisolism and ALS. Corcept is known for its innovative contributions to medication for Cushing’s syndrome through its FDA-approved drug, Korlym.
Read more →CORTCorcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
Corcept Therapeutics announced the presentation of results from the CATALYST clinical trial at the American Diabetes Association's Scientific Sessions. This study, which enrolled 1,055 patients, identified a 24% prevalence of hypercortisolism in individuals with difficult-to-control type 2 diabetes. The findings suggest that hypercortisolism is more common than previously thought and may contribute to poorer diabetes management. Insights from the study could impact screening practices and treatment effectiveness for affected patients.
Read more →CORTCorcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
Corcept Therapeutics has announced the upcoming presentations of results from the Phase 3 GRACE trial for relacorilant, aimed at treating hypercortisolism, at two significant conferences in June. The findings will be presented in a late-breaking poster session at the Endocrine Society annual meeting and an oral session at the Heart in Diabetes conference. Relacorilant, a selective cortisol modulator, is also under investigation for other serious disorders beyond Cushing's syndrome, which highlights Corcept's ongoing commitment to developing novel treatments for severe endocrinologic disorders.
Read more →CORT▲ +14.9%on this news
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
Corcept Therapeutics has announced that its Phase 3 GRACE trial for relacorilant in patients with Cushing's syndrome met its primary endpoint. The trial's initial phase showed significant improvements in hypertension and hyperglycemia among participants. In the randomized withdrawal phase, relacorilant was well-tolerated and proved more effective than placebo. Additional results are expected to be presented at upcoming medical conferences, and Corcept plans to submit a New Drug Application in the third quarter of 2024.
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif., (
Corcept Therapeutics announced a strong financial performance for Q1 2024, reporting a 39% revenue increase to $146.8 million compared to the previous year, alongside a rise in net income per share to $0.25. The company also updated its revenue expectations for the full year, raising guidance to between $620 million and $650 million. In clinical development, Corcept is advancing multiple trials, with promising results expected soon from various pivotal studies, including those related to their lead candidate, relacorilant. The company continues to focus on addressing serious medical conditions through innovative cortisol modulation therapies.
Read more →CORTCorcept Completes Enrollment in Phase 4 CATALYST Trial
Corcept Therapeutics has announced the completion of patient enrollment in the Phase 4 CATALYST trial, which investigates hypercortisolism prevalence among patients with difficult-to-control type 2 diabetes. The trial has enrolled over 1,000 patients, with an unexpectedly high identification rate of 25% for hypercortisolism. Findings from the trial will be shared at the upcoming American Diabetes Association’s Scientific Sessions, aiming to improve diagnosis and treatment strategies for affected patients.
Read more →CORTCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
Corcept Therapeutics announced positive results from the open-label phase of its Phase 3 GRACE trial for relacorilant, a treatment for Cushing's syndrome. The trial involved 152 patients who demonstrated clinically meaningful improvements in hypertension and hyperglycemia without significant safety concerns. The company is set to present further data at a medical conference in June and aims to submit a New Drug Application (NDA) for relacorilant in the current quarter. These findings may position relacorilant as a potential new standard of care for the treatment of this disease.
Read more →CORTCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
Corcept Therapeutics announced the completion of enrollment in its Phase 2 DAZALS trial assessing dazucorilant for treating amyotrophic lateral sclerosis (ALS). The trial enrolled 249 patients, who will receive varying doses of the drug or a placebo over 24 weeks, with a focus on assessing motor impairment using the ALS Functional Rating Scale. Bill Guyer, Corcept's Chief Development Officer, highlighted the urgent need for better ALS treatments and expressed optimism about the drug's potential near the end of the year.
Read more →CORTCorcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
Corcept Therapeutics has announced the completion of patient enrollment in the pivotal Phase 3 ROSELLA trial, investigating relacorilant in combination with nab-paclitaxel for treating platinum-resistant ovarian cancer. This trial follows a positive Phase 2 study that demonstrated improved patient outcomes without significant added side effects. With approximately 20,000 women eligible for new therapy each year in the U.S., the results of the ROSELLA trial could significantly impact treatment standards. The trial's primary endpoint is progression-free survival, with data expected by the end of the year.
Read more →CORTCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
Corcept Therapeutics has completed enrollment in its Phase 3 GRADIENT trial for relacorilant, a treatment for Cushing's syndrome caused by adrenal adenoma or hyperplasia. This study is noteworthy as it is the first placebo-controlled trial focused solely on patients with this condition. A total of 137 patients were randomized to receive either relacorilant or placebo for 22 weeks, targeting improvements in glucose metabolism and hypertension. Results from the trial are expected by the fourth quarter of 2024.
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif., (
Corcept Therapeutics reported robust financial results for Q4 2023, with revenues of $135.4 million, a 31% increase from Q4 2022. The full-year revenue reached $482.4 million, marking a 20% rise compared to the previous year. The company is optimistic about its 2024 revenue guidance of $600 - $630 million, while major advancements in clinical trials are underway, including potential NDA submissions for relacorilant for Cushing's syndrome. However, a decline in cash and investments and dependencies on trial outcomes present risks to sustained growth.
Read more →CORTCorcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
Corcept Therapeutics has announced its fourth-quarter and full-year financial results for 2023, showcasing a significant increase in revenue and net income. The company reported fourth-quarter revenue of $135.4 million, a 31% increase year-over-year, and full-year revenue of $482.4 million, a 20% growth from the previous year. Additionally, Corcept is on track to submit a New Drug Application for relacorilant in Cushing's syndrome within the second quarter of 2024. However, the company's cash and investments have decreased slightly compared to the previous year.
Read more →CORTCorcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
Corcept Therapeutics announced preliminary results from the CATALYST clinical trial, focusing on hypercortisolism in patients with difficult-to-control type 2 diabetes. The study found that 24% of the first 700 patients enrolled were identified with hypercortisolism, a rate consistent throughout the trial. These findings suggest a higher prevalence than previously assumed and highlight the need for increased awareness among diabetes care providers. Final results are set to be presented at the upcoming American Diabetes Association's Scientific Sessions in June.
Read more →CORTCorcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics announced plans to report its fourth quarter and full-year 2023 financial results on February 15, 2024, along with providing a corporate update. The company will host a conference call at 5:00 p.m. ET. As part of its commitment to transparency, participants must register in advance for access. Corcept has a history of developing cortisol modulators and is conducting advanced clinical trials in various serious medical conditions.
Read more →CORTCorcept Appoints Roberto Vieira as President, Oncology
Corcept Therapeutics has appointed Roberto Vieira as President of its oncology division, reporting directly to CEO Joseph K. Belanoff. Vieira, who previously worked at Mirati Therapeutics and Bristol-Myers Squibb, will leverage his expertise in cancer medicine commercialization. He aims to focus initially on ovarian cancer and plans to expand into additional tumors, emphasizing the potential of cortisol modulation in cancer treatment. The appointment reflects Corcept's commitment to advancing its oncology programs.
Read more →CORT▲ +13.1%on this news
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
Corcept Therapeutics reported preliminary financial results for Q4 2023 and the full year, revealing a revenue increase of 31% compared to Q4 2022, totaling $135.4 million. Additionally, the company provided a revenue guidance of $600 – $630 million for 2024 and announced a $200 million stock repurchase program. The growth in revenue reflects an increase in the awareness and treatment of Cushing’s syndrome, which is driving sales of its medication, Korlym. Corcept emphasizes the ongoing expansion in patient screening and treatment efforts, indicating potential for continued growth.
Read more →CORT▲ +13.1%on this news
Investor inquiries: ir@corcept.com Media inquiries: Communications@corcept.com www.corcept.com CORCEPT THERAPEUTICS PROVIDES FINANCIAL UPDATE AND ANNOUNCES STOCK REPURCHASE PROGRAM MENLO PARK, Calif., (
Corcept Therapeutics has announced its preliminary financial results for Q4 and the full year 2023, showcasing significant revenue growth compared to previous years. The company predicts a revenue range of $600-$630 million for 2024 and has approved a stock repurchase program worth up to $200 million. In addition, they emphasize the increasing screening and treatment rates for hypercortisolism, indicating a robust market for their medication, Korlym. These results are subject to adjustment pending the completion of an independent audit.
Read more →CORT▼ -25.6%on this news
Investor inquiries: ir@corcept.com Media inquiries: CorceptCommunications@corcept.com www.corcept.com C OURT F INDS C ORCEPT T HERAPEUTICS P ATENTS N OT I NFRINGED MENLO PARK, Calif ., (
Corcept Therapeutics announced that the Court for the District of New Jersey found that Teva Pharmaceuticals does not infringe on its U.S. Patents regarding Korlym. Corcept's CEO expressed confidence in winning an appeal, claiming that the patents are important for safely administering treatments. The company prepares to pursue its intellectual property rights vigorously, emphasizing the novelty of their discoveries. The legal ruling introduces potential challenges for Corcept in managing its patent protections.
Read more →CORTCorcept Appoints Monica Tellado as President, Emerging Markets
Corcept Therapeutics has appointed Monica Tellado as the new President for Emerging Markets, reporting to CEO Dr. Joseph K. Belanoff. Tellado brings extensive experience from her previous roles, notably as CFO at Heartflow and various senior positions at Gilead Sciences. She will lead global commercial strategies for metabolism and neurology therapeutics as Corcept advances its clinical trials, including a Phase 2b study for miricorilant in NASH. This strategic move aims to strengthen Corcept’s position in the market and enhance its therapeutic potential.
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif., (
Corcept Therapeutics reported strong financial results for Q3 2023, with revenues rising 22% year-over-year to $123.6 million and raising its revenue guidance for the year. The company has significant cash reserves and is optimistic about the upcoming clinical trial results, particularly for relacorilant in Cushing's syndrome and other serious disorders. Key trials are expected to yield important data by the end of 2024, enhancing the understanding and treatment of conditions such as Cushing's syndrome, ALS, and ovarian cancer.
Read more →CORTCorcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
Corcept Therapeutics has initiated the MONARCH Phase 2b trial to evaluate miricorilant in adult patients with non-alcoholic steatohepatitis (NASH). This randomized, double-blind study will involve 150 patients over 48 weeks, testing the safety and efficacy of miricorilant compared to a placebo. The trial aims to achieve a reduction in liver fat, with additional goals of NASH resolution and fibrosis improvement. With no current approved treatments for NASH, the trial's success could open new avenues for addressing this serious condition.
Read more →CORTCorcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics has scheduled a conference call for November 1, 2023, to announce its third quarter financial results and provide a corporate update. Participants must register in advance to join the call, which will also be available via a listen-only webcast. Corcept, headquartered in Menlo Park, California, has a long-standing focus on cortisol modulation, notably developing treatments for conditions like Cushing’s syndrome and conducting clinical trials for multiple serious disorders.
Read more →CORTCorcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
Corcept Therapeutics announced positive topline results from a Phase 1b study of its drug miricorilant, showing significant liver fat reduction in patients with non-alcoholic steatohepatitis (NASH). The study demonstrated a 30% decrease in liver fat and improvements in metabolic measures while being well-tolerated by participants. Corcept plans to present the findings at a scientific conference and initiate a Phase 2b trial in the fourth quarter. Miricorilant holds promise for treating a condition that currently lacks approved medications.
Read more →CORTCorcept Therapeutics Announces Final Results of Tender Offer
MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the
Read more →CORTCorcept Therapeutics Announces Preliminary Results of Tender Offer
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the
Read more →CORTCorcept Therapeutics Initiates CATALYST Clinical Trial
MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the
Read more →CORT▲ +10.4%on this news
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock
MENLO PARK, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by mo
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 AUDITED FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (
Corcept Therapeutics reported its fourth-quarter and full-year 2022 financial results, highlighting a revenue increase to $103.1 million in Q4 and $401.9 million for the year. The company anticipates 2023 revenue guidance of $430 - $450 million. Despite growth in revenue, the net income for Q4 fell to $16.6 million from $32.1 million in the previous year. Corcept is advancing its clinical programs, with several drug trials expected to progress significantly in the upcoming year.
Read more →CORTCorcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide a corporate update on February 28, 2023. The company will also host a conference c
Read more →CORTCorcept Therapeutics Investor Relations ir@corcept.com www.corcept.com C ORCEPT T HERAPEUTICS A NNOUNCES P RELIMINARY S ETTLEMENT OF P URPORTED S ECURITIES C LASS A CTION L ITIGATION MENLO PARK, Calif. (
Corcept Therapeutics has announced a preliminary settlement in a securities class action lawsuit, Melucci v. Corcept Therapeutics, requiring a one-time payment of $14.0 million, fully covered by insurance. This settlement is pending approval from the United States District Court for the Northern District of California. The litigation involves claims against Corcept and its executive officers, and while the settlement is a positive step, there are inherent risks such as the possibility of non-approval by the court and uncertainties regarding insurance coverage.
Read more →CORTCorcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the
Read more →CORTCorcept Therapeutics Investor Relations ir@corcept.com www.corcept.com C ORCEPT T HERAPEUTICS S ETTLES P ATENT L ITIGATION WITH H IKMA P HARMACEUTICALS M ENLO P ARK , Calif. (
CORCEPT THERAPEUTICS SETTLES PATENT LITIGATION WITH HIKMA PHARMACEUTICALS PARK, Calif. (December 8, 2022) Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic,
Read more →CORTCorcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the
Read more →CORTCorcept Therapeutics Provides Miricorilant Clinical Development Update
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (
CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (November 3, 2022) - Corcept Therapeutics Incorporated (NASDAQ CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve
Read more →CORTCorcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
MENLO PARK, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (
CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (August 3, 2022) - Corcept Therapeutics Incorporated (NASDAQ CORT), a commercial-stage company engaged in the discovery and development of medications to treat sever
Read more →CORTCorcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the
Read more →CORTCorcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
MENLO PARK, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (May 5, 2022) - Corcept Therapeutics Incorporated (NASDAQ CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe en
Read more →CORTCorcept Therapeutics Announces Appointment of Three Senior Leaders
MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effec
Read more →CORTCorcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain
MENLO PARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effec
Read more →CORTCorcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31, 2022
MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March 31, 2022 regarding its ovarian cancer program. Corcept will present results from the company
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2021 AUDITED FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (
CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2021 AUDITED FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (February 15, 2022) - Corcept Therapeutics Incorporated (NASDAQ CORT), a commercial stage company engaged in the discovery, development an
Read more →CORTCorcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2021 financial results and provide a corporate update on February 15, 2022. The company will also host a conference c
Read more →CORT▲ +10.3%on this news
Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer
MENLO PARK, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effect
Read more →CORT▼ -8.3%on this newsshared move
Corcept Therapeutics Announces Preliminary Results of Previously Announced Tender Offer
MENLO PARK, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effect
Read more →CORTCorcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares
MENLO PARK, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effect
Read more →CORT▼ -16.9%on this news
Corcept Therapeutics Incorporated Investor Relations ir@corcept.com www.corcept.com Corcept Therapeutics Announces Extension of Previously Announced Tender Offer
Corcept Therapeutics Announces Extension of Previously Announced Tender Offer MENLO PARK, Calif., December 8, 2021 Corcept Therapeutics Incorporated (NASDAQ: CORT) ( Corcept ) a commercial-stage company engaged in the discovery and development of drugs to treat severe metaboli
Read more →CORT▼ -16.9%on this news
Corcept Therapeutics Announces Extension of Previously Announced Tender Offer
MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects
Read more →CORTCorcept Therapeutics to Present at Upcoming Investor Conferences
MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of th
Read more →CORT▲ +10.7%on this newsshared move
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 10 Million Shares of its Common Stock
MENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects
Read more →CORTCorcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021
Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial to be featured in a proffered paper oral presentation at the upcoming ESMO conference on September 17, 2021 Results show benefit experienced by women with recurrent platinum-resistant ovarian cancer who were
Read more →CORTInvestor Relations ir@corcept.com www.corcept.com W ILLIAM G UYER TO JOIN C ORCEPT AS C HIEF D EVELOPMENT O FFICER MENLO PARK, Calif. (
WILLIAM GUYER TO JOIN CORCEPT AS CHIEF DEVELOPMENT OFFICER MENLO PARK, Calif. (August 12, 2021) Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric d
Read more →CORTCorcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2021. The company will also host a conference call that day at 5:00 p.
Read more →CORTCORCEPT THERAPEUTICS SETTLES PATENT LITIGATION WITH SUN PHARMACEUTICAL MENLO PARK, Calif. (
CORCEPT THERAPEUTICS SETTLES PATENT LITIGATION WITH SUN PHARMACEUTICAL MENLO PARK, Calif. (June 15, 2021) - Corcept Therapeutics Incorporated (NASDAQ CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psyc
Read more →CORTCORCEPT THERAPEUTICS APPOINTS JOSHUA M. MURRAY TO BOARD OF DIRECTORS MENLO PARK, Calif. (
CORCEPT THERAPEUTICS APPOINTS JOSHUA M. MURRAY TO BOARD OF DIRECTORS MENLO PARK, Calif. (Jun. 10, 2021) - Corcept Therapeutics Incorporated (NASDAQ CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychi
Read more →CORTCORCEPT THERAPEUTICS PROVIDES CLINICAL UPDATE AND ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS In a 178-patient, controlled, Phase 2 trial, women with platinum resistant ovarian cancer who received relacorilant plus na
CORCEPT THERAPEUTICS PROVIDES CLINICAL UPDATE AND ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS In a 178-patient, controlled, Phase 2 trial, women with platinum resistant ovarian cancer who received relacorilant plus nab-paclitaxel experienced improved progression free survival
Read more →CORTCorcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH)
MENLO PARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol
Read more →CORTCorcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda ) in Patients with Adrenal Cancer with Cortisol Excess
MENLO PARK, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortis
Read more →CORTCorcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer
MENLO PARK, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the ho
Read more →CORTChristopher S. James, MD Director, Investor Relations Corcept Therapeutics 650-684-8725 cjames@corcept.com www.corcept.com C ORCEPT T HERAPEUTICS E XPANDS E XECUTIVE T EAM ; A TABAK M OKARI J OINS AS C HIEF F IN
CORCEPT THERAPEUTICS EXPANDS EXECUTIVE TEAM; ATABAK MOKARI JOINS FINANCIAL OFFICER; CHARLES ROBB NAMED CHIEF BUSINESS OFFICER MENLO PARK, Calif. (March 1, 2021) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and develop
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2020 AUDITED FINANCIAL RESULTS 2020 revenue of $353.9 million, compared to $306.5 million in 2019 Fourth quarter revenue of $85.7 million, compared to $87.9 mil
CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2020 AUDITED FINANCIAL RESULTS 2020 revenue of $353.9 million, compared to $306.5 million in 2019 Fourth quarter revenue of $85.7 million, compared to $87.9 million in 2019 2020 GAAP net income of $106.0 million, com
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER, FULL-YEAR 2020 PRELIMINARY SELECTED FINANCIAL RESULTS AND 2021 REVENUE GUIDANCE PROVIDES CORPORATE UPDATE Financial Highlights, 2021 Revenue Guidance and Legal Update Prelim
CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER, FULL-YEAR 2020 PRELIMINARY SELECTED FINANCIAL RESULTS AND 2021 REVENUE GUIDANCE PROVIDES CORPORATE UPDATE Financial Highlights, 2021 Revenue Guidance and Legal Update Preliminary 2020 revenue $353.9 million, compared to $306.5 mi
Read more →CORTCorcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial results and provide a corporate update on February 8, 2021. The company will host a co
Read more →CORTCORCEPT THERAPEUTICS APPOINTS GILLIAN M. CANNON, PHD, TO BOARD OF DIRECTORS MENLO PARK, Calif. (
CORCEPT THERAPEUTICS APPOINTS GILLIAN M. CANNON, PHD, TO BOARD OF DIRECTORS MENLO PARK, Calif. (Nov. 23, 2020) - Corcept Therapeutics Incorporated (NASDAQ CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and
Read more →CORTU.S. PATENT TRIAL AND APPEALS BOARD AFFIRMS VALIDITY OF ALL CLAIMS OF CORCEPT'S U.S. PATENT NO. 10,195,214 MENLO PARK, Calif. (
U.S. PATENT TRIAL AND APPEALS BOARD AFFIRMS VALIDITY OF ALL CLAIMS OF CORCEPT'S U.S. PATENT NO. 10,195,214 MENLO PARK, Calif. (November 18, 2020) - Corcept Therapeutics Incorporated (NASDAQ CORT), a commercial-stage company engaged in the discovery and development of drugs to t
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (
CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (November 3, 2020) - Corcept Therapeutics Incorporated (NASDAQ CORT), a commercial-stage company engaged in the discovery and development of drugs to treat sever
Read more →CORTCorcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic Medication
MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortis
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (
CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (August 4, 2020) - Corcept Therapeutics Incorporated (NASDAQ CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe
Read more →CORTCorcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing’s Syndrome of Adrenal Origin
MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortiso
Read more →CORTCorcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer
MENLO PARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortiso
Read more →CORTCorcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
MENLO PARK, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortiso
Read more →CORTCorcept Therapeutics to Present Data at the American Association of Cancer Research Annual Meeting
MENLO PARK, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortiso
Read more →CORTCorcept Therapeutics to Present Data at the American Society of Clinical Oncology Annual Meeting
MENLO PARK, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (May 4, 2020) - Corcept Therapeutics Incorporated (NASDAQ CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe meta
Read more →CORTCorcept Therapeutics Publishes Abstract in The Journal of the Endocrine Society
MENLO PARK, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cort
Read more →CORTCorcept Therapeutics Appoints Gregg Alton to Board of Directors MENLO PARK, Calif. (
Corcept Therapeutics Appoints Gregg Alton to Board of Directors MENLO PARK, Calif. (March 12, 2020) - Corcept Therapeutics Incorporated (NASDAQ CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatri
Read more →CORTCorcept Therapeutics Announces Fourth Quarter And Full-Year 2019 Audited Financial Results And Provides Corporate Update MENLO PARK, Calif. (
Corcept Therapeutics Announces Fourth Quarter And Full-Year 2019 Audited Financial Results And Provides Corporate Update MENLO PARK, Calif. (February 20, 2020) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development
Read more →CORTCorcept Therapeutics to Announce Audited Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its audited 2019 fourth quarter and full-year financial results and provide a corporate update on February 20, 2020. The company will host a confe
Read more →CORTCORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 PRELIMINARY SELECTED FINANCIAL RESULTS; PROVIDES 2020 REVENUE GUIDANCE 2019 revenue of $306.5 million, an increase of 22 percent from 2018 Fourth quarter r
CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 PRELIMINARY SELECTED FINANCIAL RESULTS; PROVIDES 2020 REVENUE GUIDANCE MENLO PARK, Calif. (January 30, 2020) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery a
Read more →CORTCorcept Therapeutics Announces Third Quarter 2019 Financial Results and Provides Corporate Update MENLO PARK, Calif. (
Corcept Therapeutics Announces Third Quarter 2019 Financial Results and Provides Corporate Update MENLO PARK, Calif. (November 7, 2019) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat sever
Read more →CORTCorcept Therapeutics Appoints Kimberly Park to Board of Directors
MENLO PARK, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the st
Read more →CORTChristopher S. James, MD Director, Investor Relations Corcept Therapeutics 650-684-8725 cjames@corcept.com www.corcept.com CORCEPT THERAPEUTICS APPOINTS KIMBERLY PARK TO BOARD OF DIRECTORS MENLO PARK, Calif. (
Christopher S. James, MD Director, Investor Relations Corcept Therapeutics CORCEPT THERAPEUTICS APPOINTS KIMBERLY PARK TO BOARD OF DIRECTORS MENLO PARK, Calif. (September 18, 2019) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the d
Read more →CORTCorcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome
MENLO PARK, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the administration of Korlym® with food. The patent wi
Read more →CORTCorcept Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update
MENLO PARK, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the str
Read more →CORTCorcept Therapeutics to Present Data from Phase 1/2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Solid Tumors at the American Society of Clinical Oncology Annual Meeting
MENLO PARK, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortis
Read more →CORTCorcept Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update
MENLO PARK, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stre
Read more →CORTCorcept Therapeutics to Present Data at the 2019 American Association of Clinical Endocrinologists’ 28th Annual Congress
MENLO PARK, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the st
Read more →CORTCORCEPT THERAPEUTICS INCORPORATED INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Corcept Therapeutics Incorporated
NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Corcept Therapeutics Incorporated (“C
Read more →CORTCorcept Therapeutics Announces Poster Presentations at the 2019 Annual Meeting of the Endocrine Society Meeting
MENLO PARK, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the st
Read more →CORTCorcept (CORT) Class Action Lawsuit: Bernstein Liebhard LLP Announces a Securities Class Action Lawsuit Against Corcept Therapeutics Incorporated – CORT
NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Corcept Therapeutics Incorporated (
Read more →CORTCorcept Therapeutics Incorporated (CORT) Bronstein, Gewirtz & Grossman, LLC Announces Class Action and Lead Deadline: May 13, 2019
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC announces investors that a class action lawsuit has been filed against Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NYSE: CORT) and certain of its officers,
Read more →CORTCorcept Therapeutics Appoints Former Amgen Development Executive, Andreas Grauer, M.D., as Chief Medical Officer
MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the st
Read more →CORTCorcept Therapeutics Announces fourth quarter and full-year 2018 Audited Financial Results and provides corporate update
MENLO PARK, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the str
Read more →CORTCorcept Therapeutics To Announce Audited Financial Results, Provide Corporate Update And Host Conference Call
MENLO PARK, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its audited 2018 fourth quarter and full-year financial results and provide a corporate update on February 25, 2019. The company will host a confe
Read more →CORTCharles Robb Chief Financial Officer Corcept Therapeutics 650-688-8783 crobb@corcept.com www.corcept.com Some Important Facts about Corcept, Physicians and Patients Our FDA-approved medication, Korlym , has save
Some Important Facts about Corcept, Physicians and Patients Our FDA-approved medication, Korlym , has saved the lives of some patients and greatly improved the health of many more. Our increasingly successful commercial activities, which adhere to the highest ethical standards,
Read more →CORTCorcept Therapeutics Announces Fourth Quarter and Full-Year 2018 Preliminary Selected Financial Results; Provides 2019 Revenue Guidance
2018 revenue of $251.2 million, an increase of 58 percent from 2017 Fourth quarter revenue of $66.8 million, an increase of 25 percent from fourth quarter 2017 Repurchase in the fourth quarter of 1.1 million shares of common stock, pursuant to the company’s stock repurchase pro
Read more →CORTCorcept Therapeutics Announces First Patient Dosed in Phase 3 Trial of Relacorilant to Treat Patients with Cushing’s Syndrome
MENLO PARK, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the s
Read more →CORTCorcept Therapeutics Announces Third Quarter 2018 Financial Results and Provides Corporate Update
MENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the s
Read more →CORTCorcept Therapeutics Receives Orphan Designation for Relacorilant as Treatment for Pancreatic Cancer
MENLO PARK, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the s
Read more →CORTCorcept Therapeutics Announces Second Quarter 2018 Financial Results and Stock Repurchase Program; Provides Clinical Update
MENLO PARK, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the s
Read more →CORTCorcept Therapeutics Announces Positive Relacorilant Data at the 2018 American Society of Clinical Oncology Meeting
MENLO PARK, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the
Read more →CORTCorcept Therapeutics Announces Presentations at the American Association of Clinical Endocrinologists 27th Annual Congress
MENLO PARK, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the e
Read more →CORTCorcept Therapeutics Announces First Quarter 2018 Financial results and Provides Corporate Update
MENLO PARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the str
Read more →CORTCorcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals for Infringement of Korlym Patents
MENLO PARK, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the s
Read more →CORTCorcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial
MENLO PARK, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the st
Read more →CORTCorcept Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results, Provide Corporate Update, Host Conference Call
MENLO PARK, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report its 2017 financial results and provide a corporate update on February 22, 2018. The Company will also host a conference call that day at 5:00 p.m
Read more →CORTCorcept Therapeutics Announces Fourth Quarter and Full-Year 2017 Preliminary Selected Financial Results; Provides 2018 Revenue Guidance
2017 revenue of $159.2 million, an increase of 96 percent from 2016 Fourth quarter revenue of $53.3 million, an increase of 124 percent from fourth quarter 2016 Cash and marketable securities at December 31, 2017 of $104.0 million 2018 revenue guidance of $275 – 300 million M
Read more →CORTCorcept Therapeutics Announces Third Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
MENLO PARK, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the st
Read more →CORTCorcept Therapeutics Announces Second Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
Commercial & Financial Highlights Revenue of $35.6 million in second quarter 2017, an increase of 80 percent from second quarter 2016 2017 revenue guidance increased by $20 million, to $145-155 million GAAP net income of $0.10 per share, compared to $0.01 per share in second q
Read more →CORTCorcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism at the American Association of Clinical Endocrinologists 26th Annual Congress
MENLO PARK, CA--(Marketwired - May 4, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects
Read more →CORTCorcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
MENLO PARK, CA--(Marketwired - May 1, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Revenue of $27.6 million in the first quarter of 2017, a 72 percent increase from the first quarter of 2016 2017 revenue guidance increased to $125-135 million GAAP net income of $0.
Read more →CORTCharles Robb Chief Financial Officer Corcept Therapeutics 650-688-8783 crobb@corcept.com www.corcept.com CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER 2017 FINANCIAL RESULTS, RAISES 2017 REVENUE GUIDANCE AND PROV
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER 2017 FINANCIAL RESULTS, RAISES 2017 REVENUE GUIDANCE AND PROVIDES CORPORATE UPDATE Calif. (May 1, 2017) Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercializ
Read more →CORTCorcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call
MENLO PARK, CA--(Marketwired - Apr 24, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2017. The Company will also host a conference call that day at 5:00 p.m. Eastern
Read more →CORTCorcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017 Revenue Guidance
MENLO PARK, CA--(Marketwired - Mar 6, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT) 2016 revenue of $81.3 million, a 62 percent increase from 2015 Fourth quarter 2016 revenue of $23.8 million, a 59 percent increase from fourth quarter 2015 2016 GAAP net income of $8
Read more →CORTCorcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance
MENLO PARK, CA--(Marketwired - Jan 30, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT) 2016 revenue of $81.3 million, a 62 percent increase from 2015 Fourth quarter 2016 revenue of $23.8 million, a 59 percent increase from fourth quarter 2015 Preliminary fourth quarte
Read more →CORTCorcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call
MENLO PARK, CA--(Marketwired - Jan 23, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report preliminary fourth quarter and full year 2016 financial results and provide 2017 revenue guidance and a corporate update on January 30, 2017. The company
Read more →CORTCorcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer
MENLO PARK, CA--(Marketwired - Dec 10, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating the effect
Read more →CORTCorcept Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update
MENLO PARK, CA--(Marketwired - Nov 1, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Financial Highlights Third quarter revenue of $21.7 million, a 64 percent increase from the third quarter of 2015 Third quarter GAAP net income of $0.02 per share, compared to a GAAP
Read more →CORTCorcept Therapeutics to Announce Third Quarter 2016 Financial Results and Corporate Update and Host Conference Call
MENLO PARK, CA--(Marketwired - Oct 26, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 1, 2016. The Company will also host a conference call that day at 5:00 p.m. Ea
Read more →CORTCharles Robb Chief Financial Officer Corcept Therapeutics 650-688-8783 crobb@corcept.com www.corcept.com CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER 2016 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Second
CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER 2016 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. (August 2, 2016) Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drug
Read more →CORTCorcept Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update
MENLO PARK, CA--(Marketwired - Aug 2, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Second quarter revenue of $19.7 million, a 65 percent increase from the second quarter of 2015 Second quarter GAAP net income of $0.01 per share, compared to a GAAP net loss of $0.02
Read more →CORTCorcept Therapeutics to Announce Second Quarter 2016 Financial Results and Corporate Update and Host Conference Call
MENLO PARK, CA--(Marketwired - Jul 26, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 2, 2016. The Company will also host a conference call that day at 5:00 p.m. Eas
Read more →CORTCharles Robb Chief Financial Officer Corcept Therapeutics 650-688-8783 crobb@corcept.com www.corcept.com CORCEPT THERAPEUTICS APPOINTS RENÉE D. GALÁ TO BOARD OF DIRECTORS MENLO PARK, Calif. (
CORCEPT THERAPEUTICS APPOINTS REN E D. GAL TO BOARD OF DIRECTORS MENLO PARK, Calif. (June 28, 2016) Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psych
Read more →CORTCorcept Therapeutics Appoints Renee D. Gala to Board of Directors
MENLO PARK, CA--(Marketwired - Jun 28, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating the effect
Read more →CORTCorcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program
MENLO PARK, CA--(Marketwired - Jun 2, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Preliminary efficacy results in Phase 1/2 trial of mifepristone plus eribulin (Eisai's Halaven ) to treat triple-negative breast cancer (TNBC) indicate combination is active; final res
Read more →CORTCorcept Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update
MENLO PARK, CA--(Marketwired - May 3, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) First quarter revenue of $16.1 million, a 59 percent increase from the first quarter of 2015 Excluding non-cash expenses, first quarter non-GAAP net income of $0.02 per share, compare
Read more →CORTCorcept Therapeutics Announces 2015 Financial Results
MENLO PARK, CA--(Marketwired - Mar 1, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Full year 2015 revenue of $50.3 million, an 89 percent increase from 2014 Fourth quarter 2015 revenue of $15.0 million, a 66 percent increase from the fourth quarter of 2014 GAAP net
Read more →CORTCorcept Therapeutics Announces Preliminary Fourth Quarter and Full Year 2015 Summary Financial Results, Provides 2016 Revenue Guidance and Corporate Update
MENLO PARK, CA--(Marketwired - Jan 28, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Full year 2015 revenue of $50.3 million, an 89 percent increase from 2014 Fourth quarter 2015 revenue of $15.0 million, a 66 percent increase from the fourth quarter of 2014 2016 re
Read more →CORTCorcept Therapeutics to Announce Preliminary 2015 Financial Results, Provide 2016 Revenue Guidance and Corporate Update, and Host Conference Call
MENLO PARK, CA--(Marketwired - Jan 21, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report preliminary fourth quarter and full year 2015 financial results and provide 2016 revenue guidance and a corporate update on January 28, 2016. The company
Read more →CORTCorcept Therapeutics Announces Initial Efficacy Results in Phase 1/2 Trial of Mifepristone in Combination With Eribulin for the Treatment of Patients With Metastatic Triple-Negative Breast Cancer
MENLO PARK, CA--(Marketwired - Dec 14, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating activity a
Read more →CORTCorcept Therapeutics Announces Third Quarter 2015 Results and Provides Corporate Update
MENLO PARK, CA--(Marketwired - Nov 5, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT) GAAP net loss in the third quarter narrows to $0.6 million, from $6.0 million in the third quarter of 2014 Non-GAAP net income in the third quarter increases to $1.6 million, compared
Read more →CORTCorcept Therapeutics to Announce Third Quarter Financial Results and Corporate Update and Host Conference Call
MENLO PARK, CA--(Marketwired - Oct 29, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 5, 2015. The Company will also host a conference call that day at 5:00 p.m. Ea
Read more →CORTCorcept Therapeutics Appoints Robert S. Fishman, M.D., as Chief Medical Officer
MENLO PARK, CA--(Marketwired - Sep 28, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, announced tod
Read more →CORTCorcept Therapeutics Announces Second Quarter 2015 Results and Provides Corporate Update
MENLO PARK, CA--(Marketwired - Aug 5, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Per-share net loss in the second quarter narrows to $0.02, from $0.07 in the same period last year Excluding non-cash expenses, non-GAAP net income for the second quarter is $369,000,
Read more →CORTCorcept Therapeutics to Announce Second Quarter Financial Results and Corporate Update and Host Conference Call
MENLO PARK, CA--(Marketwired - Jul 29, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 5, 2015. The Company will also host a conference call that day at 5:00 p.m. Eas
Read more →CORTCorcept Therapeutics Appoints Daniel Swisher to Board of Directors
MENLO PARK, CA--(Marketwired - Jun 22, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, announced tod
Read more →CORTCorcept Therapeutics Announces Poster Presentations on Mifepristone for the Treatment of Patients With Cushing's Syndrome at the 27th Annual American Association of Clinical Endocrinologists
MENLO PARK, CA--(Marketwired - May 14, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today announc
Read more →CORTCorcept Therapeutics' Mifepristone Combined With Eribulin to Improve Antitumor Activity in Patients With Triple-Negative Breast Cancer
MENLO PARK, CA--(Marketwired - May 13, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effect
Read more →CORTCorcept Therapeutics Announces First Quarter 2015 Results and Provides Corporate Update
MENLO PARK, CA--(Marketwired - May 7, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Per-share net loss in first quarter narrows to $0.05, from $0.14 in the same period last year First quarter revenue is $10.1 million, compared to $4.4 million in the first quarter 201
Read more →CORTCorcept Therapeutics Announces Nine Poster Presentations on Mifepristone for the Treatment of Cushing's Syndrome at the 97th Annual Endocrine Society Meeting
MENLO PARK, CA--(Marketwired - Mar 5, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today announce
Read more →CORTCorcept Therapeutics Announces 2014 Financial Results and Provides Clinical Update
MENLO PARK, CA--(Marketwired - Mar 4, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Q4 net loss narrowed to $0.04 per share, down from $0.11 per share in the same period in 2013 Excluding non-cash expenses, Q4 non-GAAP net loss declined to $0.02 per share, compared t
Read more →CORTCorcept Therapeutics Announces Fourth Quarter and Full Year 2014 Revenue, Provides 2015 Revenue Guidance and Clinical Update
MENLO PARK, CA--(Marketwired - Jan 29, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Fourth quarter 2014 revenue grows to $9.0 million, a 24 percent increase from the prior quarter and a 119 percent increase from the same period last year Full year 2014 revenue of $2
Read more →CORTCorcept Therapeutics to Announce Fourth Quarter and Full Year 2014 Revenue and Corporate Update and Host Conference Call
MENLO PARK, CA--(Marketwired - Jan 22, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full year 2014 revenue on January 29, 2015. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m.
Read more →CORTCorcept Therapeutics Announces Third Quarter 2014 Financial Results and Provides Corporate Update
MENLO PARK, CA--(Marketwired - Nov 4, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today reported
Read more →CORTCorcept Therapeutics to Announce Third Quarter Financial Results and Host Conference Call
MENLO PARK, CA--(Marketwired - Oct 28, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2014. The Company will also host a conference call that day at 5:00 p.m. Ea
Read more →CORTCorcept Therapeutics Announces Second Quarter 2014 Financial Results and Provides Corporate Update
MENLO PARK, CA--(Marketwired - Aug 5, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Revenue increases 33 percent from prior quarter on continued uptake of Korlym for the treatment of Cushing's syndrome GAAP net loss narrows to $0.07 per share; non-GAAP net loss narro
Read more →CORTCorcept Therapeutics to Announce Second Quarter Financial Results and Host Conference Call
MENLO PARK, CA--(Marketwired - Jul 29, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 5, 2014. The Company will also host a conference call that day at 5:00 p.m. Eas
Read more →CORTCorcept Therapeutics Announces First Quarter 2014 Financial Results
MENLO PARK, CA--(Marketwired - May 7, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today reported
Read more →CORTCorcept Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
MENLO PARK, CA--(Marketwired - Mar 5, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today reported
Read more →CORTCorcept Therapeutics Announces Fourth Quarter, Full Year 2013 Revenue and Provides 2014 Outlook
MENLO PARK, CA--(Marketwired - Jan 30, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Fourth quarter 2013 revenue up 56% over third quarter 2013 revenue Company anticipates Korlym 2014 revenue to grow to a range of $24 million to $28 million, up from $10.4 million in
Read more →CORTCorcept Therapeutics to Announce Fourth Quarter and Full Year Revenue and Corporate Update and Host Conference Call
MENLO PARK, CA--(Marketwired - Jan 27, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full year 2013 revenue on January 30, 2014. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m.
Read more →CORTCorcept Therapeutics Announces Oncology Development Program
SAN ANTONIO, TX--(Marketwired - Dec 12, 2013) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, announced pl
Read more →CORTCorcept Therapeutics Announces Third Quarter 2013 Financial Results and Corporate Update
MENLO PARK, CA--(Marketwired - Nov 7, 2013) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financ
Read more →CORTCorcept Therapeutics to Announce Third Quarter 2013 Financial Results and Host Conference Call
MENLO PARK, CA--(Marketwired - Nov 4, 2013) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter 2013 financial results on November 7, 2013. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Ti
Read more →CORTCorcept Therapeutics Announces Second Quarter 2013 Financial Results and Corporate Update
MENLO PARK, CA--(Marketwired - Aug 8, 2013) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financ
Read more →CORTCorcept Therapeutics to Announce Second Quarter 2013 Financial Results and Host Conference Call
MENLO PARK, CA--(Marketwired - Aug 1, 2013) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter 2013 financial results on August 8, 2013. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Tim
Read more →CORTCorcept Therapeutics Announces Partnership With Idis for Global Access to Korlym(R)
PRINCETON, NJ and MENLO PARK, CA--(Marketwired - Jul 24, 2013) - Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that Korlym (mifepristone) 300 mg Tablets is available to patients outside of the United States through an Idis Access Program. Idis Access Programs e
Read more →CORTCorcept Therapeutics Announces First Quarter 2013 Financial Results
MENLO PARK, CA--(Marketwired - May 2, 2013) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financ
Read more →CORTCorcept Therapeutics to Announce First Quarter 2013 Financial Results and Host Conference Call
MENLO PARK, CA--(Marketwired - Apr 26, 2013) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter 2013 financial results on May 2, 2013. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Read more →CORTCorcept Therapeutics Announces Fourth Quarter and Full Year 2012 Financial Results
MENLO PARK, CA--(Marketwire - Mar 7, 2013) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financi
Read more →CORTCorcept Therapeutics Announces Fourth Quarter and Full Year Revenue and Corporate Update
MENLO PARK, CA--(Marketwire - Feb 12, 2013) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its unaudi
Read more →CORTCorcept Therapeutics Announces Third Quarter Results and Corporate Update
MENLO PARK, CA--(Marketwire - Oct 31, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financ
Read more →CORTCorcept Therapeutics Appoints Daniel M. Bradbury to Board of Directors
MENLO PARK, CA--(Marketwire - Oct 15, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, announced today that Dani
Read more →CORTCorcept Therapeutics Announces Second Quarter Results and Corporate Update
MENLO PARK, CA--(Marketwire - Aug 7, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financi
Read more →CORTCorcept Therapeutics Announces $30 Million Synthetic, Capped Royalty Transaction; Terminates Committed Equity Financing Facility
MENLO PARK, CA--(Marketwire - Aug 7, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today announced that it ha
Read more →CORTCorcept Therapeutics Announces Underwritten Public Offering of Common Stock
MENLO PARK, CA--(Marketwire - Jul 2, 2012) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today announce
Read more →CORTCorcept Therapeutics Commences Public Offering of Common Stock
MENLO PARK, CA--(Marketwire - Jul 2, 2012) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today announce
Read more →CORTCorcept Therapeutics Announces First Quarter Results and Corporate and Development Update
MENLO PARK, CA--(Marketwire - May 3, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today updated its corporat
Read more →CORTCorcept Therapeutics Announces National Product Launch of Korlym(TM) for Patients With Endogenous Cushing's Syndrome
MENLO PARK, CA--(Marketwire - Apr 10, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that Korlym (mifepristone) 300 mg Tablets is available by prescription nationwide. On February 17, 2012, the U.S. Food and Drug Administration (FDA) approved Korlym as
Read more →CORTCorcept Therapeutics Announces Exercise of Warrants and Private Placement of New Warrants
MENLO PARK, CA--(Marketwire - Mar 26, 2012) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today announc
Read more →CORTCorcept Therapeutics Announces Fourth Quarter Results and Corporate and Development Update
MENLO PARK, CA--(Marketwire - Mar 5, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today updated its corporat
Read more →CORTCorcept Therapeutics Incorporated Announces FDA Approval of Korlym(TM) (Mifepristone): First and Only Approved Medication for Cushing's Syndrome Patients
MENLO PARK, CA--(Marketwire - Feb 17, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that the U.S. Food and Drug Administration (FDA) has approved Korlym (mifepristone 300 mg tablets) as a once-daily oral medicine to control hyperglycemia secondary to hy
Read more →CORTCorcept Therapeutics Announces Third Quarter Results and Corporate and Development Update
MENLO PARK, CA--(Marketwire - Nov 7, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported financial r
Read more →CORTCorcept Therapeutics Announces Second Quarter Results and Corporate and Development Update
MENLO PARK, CA--(Marketwire - Aug 8, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported financial r
Read more →CORTCorcept Therapeutics Announces Detailed Findings From Phase 3 Study Which Show CORLUX Significantly Improves Clinical and Metabolic Manifestations of Cushing's Syndrome
MENLO PARK, CA--(Marketwire - Jun 4, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today announced detailed d
Read more →CORTCorcept Therapeutics Announces Conference Call to Discuss Detailed Findings From Corlux Phase 3 Trial in Cushing's Syndrome at the Endocrine Society's Annual Meeting
MENLO PARK, CA--(Marketwire - Jun 1, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today announced that it wi
Read more →CORTCorcept Therapeutics to Present Detailed Findings From CORLUX Phase 3 Trial in Cushing's Syndrome at the Endocrine Society's Annual Meeting, June 4-7
MENLO PARK, CA--(Marketwire - May 19, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today announced that deta
Read more →CORTCorcept Therapeutics Announces NDA Submitted to the FDA for the Use of CORLUX in Cushing's Syndrome
MENLO PARK, CA--(Marketwire - Apr 15, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today announced that it h
Read more →CORTCorcept Therapeutics Announces NDA Submission to Be Completed the Week of April 11, 2011
MENLO PARK, CA--(Marketwire - March 31, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today announced that it
Read more →CORTCorcept Therapeutics Announces Closing of $44.9 Million Underwritten Public Offering of Common Stock
MENLO PARK, CA--(Marketwire - January 26, 2011) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today announced the closing
Read more →CORTCorcept Therapeutics Announces Pricing of $39.0 Million Underwritten Public Offering of Common Stock
MENLO PARK, CA--(Marketwire - January 21, 2011) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today announced the pricing
Read more →CORTCorcept Therapeutics Announces Proposed Public Offering of Common Stock
MENLO PARK, CA--(Marketwire - January 20, 2011) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today announced that it is o
Read more →CORTCorcept Therapeutics Announces Key Secondary Endpoint Was Met in Phase 3 Study of Corlux for Cushing's Syndrome
MENLO PARK, CA--(Marketwire - January 11, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced positive results on the key secondary endpoint of "global clinical improvement" in its Phase 3 study of CORLUX for the treatment of Cushing's Syndrome. The company p
Read more →CORTCorcept Therapeutics Announces Positive Phase 3 Study Results for CORLUX for the Treatment of Cushing's Syndrome
MENLO PARK, CA--(Marketwire - December 22, 2010) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced positive top-line results from its Phase 3 study of CORLUX for the treatment of Cushing's Syndrome. The study evaluated the response of two patient groups to CORLUX
Read more →CORTCorcept Therapeutics to Hold Conference Call Wednesday December 22 at 8:30 am Eastern Time
MENLO PARK, CA--(Marketwire - December 21, 2010) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today announced that it will host a con
Read more →CORTCorcept Therapeutics Completes Enrollment in Phase 3 Cushing's Syndrome Study -- Data Announcement Anticipated by Year End
MENLO PARK, CA--(Marketwire - July 1, 2010) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today announced that it has comp
Read more →CORTCorcept Therapeutics Announces Pricing of $15 Million Underwritten Public Offering of Common Stock
MENLO PARK, CA--(Marketwire - June 25, 2010) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today announced the pricing of
Read more →CORTCorcept Therapeutics Nears Completion of Enrollment in Phase 3 Cushing's Syndrome Study -- Data Announcement Anticipated by Year End
MENLO PARK, CA--(Marketwire - June 25, 2010) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today announced that it had enr
Read more →CORTCorcept Therapeutics Announces First Quarter Results and Update on Development Programs
MENLO PARK, CA--(Marketwire - May 11, 2010) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today reported financial results for the fir
Read more →CORTCorcept Therapeutics Updates Cushing's Syndrome Development and Recent Financing
MENLO PARK, CA--(Marketwire - May 3, 2010) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today updated the status of enrollment in its
Read more →CORTCorcept Therapeutics Announces Exercise of Existing Warrants and Private Placement of Warrants
MENLO PARK, CA--(Marketwire - April 22, 2010) - Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today announced that certain e
Read more →CORTCorcept Therapeutics Announces Fourth Quarter and Full Year 2009 Results and Update on Development Programs
MENLO PARK, CA--(Marketwire - March 25, 2010) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today reported financial results for the
Read more →CORTCorcept Therapeutics Initiates a Phase 1 Study of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- CORT 108297
MENLO PARK, CA--(Marketwire - February 23, 2010) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, has begun dosing in the Phase 1 study
Read more →CORTCorcept Therapeutics Announces Four Anticipated Milestones for 2010
MENLO PARK, CA--(Marketwire - January 5, 2010) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, announces its anticipated milestones fo
Read more →CORTCorcept Therapeutics Announces Recent Highlights and Third Quarter 2009 Financial Results
MENLO PARK, CA--(Marketwire - November 10, 2009) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, today reported on recent development
Read more →CORTCorcept Therapeutics Announces Pricing of Private Placement Cash Sufficient to Fund Company Through Corlux NDA Submission
MENLO PARK, CA--(Marketwire - October 13, 2009) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the development of drugs for the treatment of severe metabolic and psychiatric disorders, today announced that it has entered into a definitiv
Read more →CORTCorcept Therapeutics Announces Second Quarter 2009 Results and Development Highlights
MENLO PARK, CA--(Marketwire - August 11, 2009) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the development of drugs for the treatment of severe metabolic and psychiatric disorders, today reported financial results for the second quart
Read more →CORTCorcept Therapeutics Announces First Quarter 2009 Results and Development Highlights
MENLO PARK, CA--(Marketwire - May 11, 2009) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and metabolic disorders, today reported financial results for the first quarter e
Read more →CORTCorcept Therapeutics Announces Fourth Quarter and Full Year 2008 Results and Update on Development Programs
MENLO PARK, CA--(Marketwire - March 30, 2009) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and metabolic disorders, today updated its corporate progress, reported financi
Read more →CORTCorcept Therapeutics Announces Third Quarter 2008 Results
MENLO PARK, CA--(Marketwire - November 13, 2008) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the third quarter ended For the third quarter of 2008, Corcept reported a net loss of $5.6 million, or $0.11 per share, compared to a net los
Read more →CORTCorcept Therapeutics Continues Collaboration With Eli Lilly and Company
MENLO PARK, CA--(Marketwire - September 3, 2008) - Corcept Therapeutics (NASDAQ: CORT) announced today that Eli Lilly and Company (Lilly) has agreed to fund studies to test the effectiveness of Corcept's selective GRII receptor antagonist, CORT 108297, in rat models of olanzap
Read more →CORTCorcept Therapeutics Announces Second Quarter 2008 Results
MENLO PARK, CA--(Marketwire - August 13, 2008) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the second quarter ended June For the second quarter of 2008, Corcept reported a net loss of $4.4 million, or $0.09 per share, compared to a ne
Read more →CORTCorcept Therapeutics Announces First Quarter 2008 Results
MENLO PARK, CA--(Marketwire - May 12, 2008) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the first quarter ended March For the first quarter of 2008, Corcept reported a net loss of $3.9 million, or $0.10 per share, compared to a net lo
Read more →CORTCorcept Therapeutics Announces Promising Results of Human Microdosing Study of Selective GR-II Antagonist
MENLO PARK, CA--(Marketwire - May 1, 2008) - Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that its lead selective GR-II antagonist, CORT 108297, produced promising results in a human microdosing study. "The compound was extremely well absorbed, demonstrated
Read more →CORTCorcept Therapeutics Announces Fourth Quarter 2007 Results
MENLO PARK, CA--(Marketwire - March 27, 2008) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the fourth quarter and for the full year ended December 31, 2007. For the fourth quarter of 2007, Corcept reported a net loss of $4.2 million,
Read more →CORTCorcept Therapeutics Completes $25 Million Private Equity Financing and Secures Committed Equity Financing Facility for up to $60 Million
MENLO PARK, CA--(Marketwire - March 26, 2008) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today confirmed that its previously announced private placement of Corcept common stock and warrants has been completed. Corcept sold approximately 8.9 million shares of its common
Read more →CORTCorcept Therapeutics Announces Commencement of Next Phase 3 Study With CORLUX(R) for the Treatment of Psychotic Depression
MENLO PARK, CA--(Marketwire - March 24, 2008) - Corcept Therapeutics (NASDAQ: CORT) today announced the commencement of its fourth Phase 3 trial, Study 14, evaluating CORLUX for the treatment of the psychotic features of psychotic depression. This trial is a randomized, double
Read more →CORTCorcept Therapeutics Announces $25.3 Million Private Equity Financing
MENLO PARK, CA--(Marketwire - March 17, 2008) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has entered into a definitive agreement with certain accredited investors for the private placement of approximately 8.9 million shares of its common stock a
Read more →CORTCorcept Therapeutics Announces Commencement of a Phase 3 Trial for CORLUX(R) for the Treatment of Endogenous Cushing's Syndrome
MENLO PARK, CA--(Marketwire - December 19, 2007) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced the commencement of its Phase 3 trial with CORLUX for the treatment of endogenous Cushing's Syndrome. CORLUX is a cortisol receptor (GR-II) antagonist. In Septem
Read more →CORTCorcept Therapeutics Announces Third Quarter 2007 Results
MENLO PARK, CA--(Marketwire - November 8, 2007) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the third quarter ended For the third quarter of 2007, Corcept reported a net loss of $3.4 million, or $0.09 per share, compared to a net loss
Read more →CORTCorcept Therapeutics Completes Second Closing Under August Private Equity Financing Agreement
MENLO PARK, CA--(Marketwire - September 25, 2007) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced the successful completion of the second closing as part of the private placement financing agreement dated August 16, 2007. On August 20, 2007, the Company annou
Read more →CORTCorcept Therapeutics Receives FDA Notification Opening IND for CORLUX(R) for the Treatment of Cushing's Syndrome
MENLO PARK, CA--(Marketwire - September 11, 2007) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has received notification from the Food and Drug Administration (FDA) that the FDA has opened the Investigational New Drug application (IND) for CORLUX f
Read more →CORTCorcept Therapeutics Announces $10.1 Million Private Equity Financing
MENLO PARK, CA--(Marketwire - August 20, 2007) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced a private placement of approximately 4.8 million shares of its common stock at a price of $2.10 per share, pursuant to a definitive agreement dated as of August 16,
Read more →CORTCorcept Therapeutics Announces Second Quarter 2007 Results
MENLO PARK, CA--(Marketwire - August 13, 2007) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the second quarter ended June For the second quarter of 2007, Corcept reported a net loss of $1.4 million, or $0.04 per share, compared to a ne
Read more →CORTCorcept Therapeutics and Xceleron Sign Agreement for Microdosing Study Using Accelerator Mass Spectrometry
MENLO PARK, CA--(Marketwire - July 25, 2007) - Corcept Therapeutics (NASDAQ: CORT) and Xceleron today announced an agreement for a human microdosing study of one of Corcept's new chemical entities, a selective GR-II antagonist, utilizing Xceleron's Accelerator Mass Spectrometr
Read more →CORTCorcept Therapeutics Receives Orphan Drug Designation for CORLUX(R) Treatment of Cushing's Syndrome
MENLO PARK, CA--(Marketwire - July 9, 2007) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has received Orphan Drug Designation from the Food and Drug Administration (FDA) for CORLUX for the treatment of Cushing's Syndrome. CORLUX is a cortisol recep
Read more →CORTCorcept Therapeutics Announces Positive Results From Its Proof of Concept Study Evaluating the Ability of CORLUX(R) to Mitigate Weight Gain Associated With Olanzapine
MENLO PARK, CA--(Marketwire - June 21, 2007) - Corcept Therapeutics (NASDAQ: CORT) today announced that preliminary top line results indicated a statistically significant reduction in weight gain in those subjects who took olanzapine plus CORLUX compared to those who took olan
Read more →CORTCorcept Therapeutics Announces First Quarter 2007 Results
MENLO PARK, CA -- (MARKET WIRE) -- May 9, 2007 --Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the first quarter ended March For the first quarter of 2007, Corcept reported a net loss of $2.5 million, or $0.10 per share, compared to a net
Read more →CORTCorcept Therapeutics Announces $9 Million Private Equity Financing
MENLO PARK, CA -- (MARKET WIRE) -- March 30, 2007 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced the completion of a private placement of 9,000,000 shares of its common stock at a price of $1.00 per share, pursuant to a definitive agreement entered into tod
Read more →CORTCorcept Therapeutics Announces Fourth Quarter 2006 Results
MENLO PARK, CA -- (MARKET WIRE) -- March 28, 2007 --Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the fourth quarter and the full year ended December 31, 2006. For the fourth quarter of 2006, Corcept reported a net loss of $3.9 million,
Read more →CORTCorcept Therapeutics Announces Chief Financial Officer Resignation
MENLO PARK, CA -- (MARKET WIRE) -- March 28, 2007 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that Fred Kurland, the Company's Chief Financial Officer, has tendered his resignation, effective April 13, 2007 to become the chief financial officer at anothe
Read more →CORTCorcept Therapeutics Announces Phase 3 Study Evaluating CORLUX(R) for Psychotic Major Depression Misses Primary Endpoint
MENLO PARK, CA -- (MARKET WIRE) -- March 19, 2007 --Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that Study 06, the last of three Phase 3 trials evaluating CORLUX for treating the psychotic features of Psychotic Major Depression (PMD), did not achieve statis
Read more →CORTCorcept Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Rule
MENLO PARK, CA -- (MARKET WIRE) -- January 16, 2007 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has received notice from the NASDAQ Staff that it has regained compliance with NASDAQ's $1.00 per share bid price requirement. This closes the matter
Read more →CORTCorcept Therapeutics Receives NASDAQ Notice of Non-Compliance
MENLO PARK, CA -- (MARKET WIRE) -- December 27, 2006 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has received a NASDAQ Staff Determination in response to the Company's December 4, 2006 submission of a plan to regain compliance with NASDAQ Marketp
Read more →CORTCorcept Therapeutics Completes $3 Million Private Equity Financing
MENLO PARK, CA -- (MARKET WIRE) -- December 15, 2006 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today confirmed that its previously announced private placement of Corcept common stock had been completed. Corcept sold 3,000,000 shares of its common stock at $1.00 per sh
Read more →Competitive Position
How CORT ranks across every disease it competes inCompetitive Position is a premium feature
See how CORT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial